The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure
Study Description
This study targets patients without hyperlipidemia or traditional indications for statin therapy. Subjects will be randomized to simvastatin 40 mg or placebo. Response to simvastatin on inflammatory markers (tissue factor, IL-1, IL-6, IL-10, TNF-a) will be measured at baseline and at study termination (3 months).Contact Information
Status:
Name, Phone, Email:
Benjamin Van Tassell
801-585-5317
Benjamin.van tassel@hsc.utah.edu
Principle Investigator:
Mark Munger
Please Note:
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician. If you do not have a primary care physician, we can help you find a University of Utah doctor or clinic location to meet your health care needs.
Although the studies described on this Web site may have potential benefits as described, the University of Utah and its physicians and affiliated hospitals cannot and do not guarantee or promise that you will receive any benefits from participating in a study.
Participant Eligibility
Inclusion Criteria:- Age Range: 18-85
- LVEF class I to III, LVEF < 40%
- Current Use of statin
- Heart failure due to active myocarditis, congenital heart disease, stenotic valvular disease
- LDL > 130 mg/dL in patients with evidence of ischemic disease (CAD, DVA, ACS, unstable angina, ischemic cardiomyopathy)
- Significant renal disease (SCr > 2.5 mg/dL) or hepatic disease (LFTs > 3 times upper limit of normal.)
